Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium

Elias Jabbour, MD, Koji Sasaki, Mikkael A. Sekeres, MD MS, Rami S Komrokji, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Roboz J Gail, MD, Naval G. Daver, MD, Naveen Pemmaraju, MD, Tapan Kadia, MD, Courtney D. DiNardo, MD, Xuemei Wang, PhD, Graciela Nogueras-Gonzalez, Gautam Borthakur, MD, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 4641.

https://doi.org/10.1182/blood.V124.21.4641.4641

Published: 2014

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in First Remission Improves Outcome Irrespective of FLT3-ITD Allelic Burden Among Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation

Betul Oran, MD, Richard E. Champlin, Jorge E. Cortes, Marcos de Lima, MD, Xuemei Wang, PhD, Hsiang-Chun Chen, Farhad Ravandi, MD, Stefan O. Ciurea, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD

Blood (2014) 124 (21): 2531.

https://doi.org/10.1182/blood.V124.21.2531.2531

Published: 2014

Journal Articles

Other Cancers in Long-Term Survivors of Chronic Lymphocytic Leukemia: Incidence and Prognostic Relevance

Lorenzo Falchi, MD, Michael Keating, MBBS, Susan Lerner, MS, Xuemei Wang, PhD, Kplola Y Elhor Gbito, MD MPH, Sara S. Strom, PhD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD

Blood (2014) 124 (21): 3323.

https://doi.org/10.1182/blood.V124.21.3323.3323

Published: 2014

Journal Articles

Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML)

Tapan Kadia, MD, Gautam Borthakur, MD, Alessandra Ferrajoli, MD, Naval Daver, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Srdan Verstovsek, MD PhD, Jan A. Burger, MD PhD, William G. Wierda, MD PhD, Marina Konopleva, MD PhD, Courtney D. DiNardo, MD, Nitin Jain, MD, Mark Brandt, Carla Tuttle, RN, Xuemei Wang, PhD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, Hagop M. Kantarjian, MD

Blood (2014) 124 (21): 3671.

https://doi.org/10.1182/blood.V124.21.3671.3671

Published: 2014

Journal Articles

Antitumor Efficacy Of DMSA Modified Fe 3 O 4 magnetic Nanoparticles Combined With Arsenic Trioxide and Adriamycin In Jurket Cells

Cai Xiaohui, Chunling Wang, Baoan Chen, PHD, Professor, Weijun Hua, Fei Shen, Liang Yu, PHD, Zhengmei He, Yue Chen, Guohua Xia, Jian Cheng, PhD,, Wen Bao, Yu Zhang, PHD, Xuemei Wang, PHD, Senthilkumar Ravichandran

Blood (2013) 122 (21): 4917.

https://doi.org/10.1182/blood.V122.21.4917.4917

Published: 2013

Journal Articles

Gambogic Acid Combined With CdTe QDs For Leukemia Cancer Cells Inhibition and Their Bio-Safety For Rat Brain

Peipei Xu, Doctor, Baoan Chen, PHD, Professor, Jingyuan Li, Doctor, Xuemei Wang, PHD, Professor

Blood (2013) 122 (21): 5028.

https://doi.org/10.1182/blood.V122.21.5028.5028

Published: 2013

Journal Articles

Hyperthermia Enhances The Effect Of Magnetic Fe 3 O 4 nanoparticle Loaded With Daunorubicin On Leukemia and Drug Accumulation In Tumor In Vivo

Ran Liu, Doctor, Weiwei Wu, Doctor, Baoan Chen, PHD, Professor, Jian Cheng, PhD, associate professor, Jun Wang, PHD, associate professor, Jia Zhang, Doctor, Wen Bao, Doctor, Xiaoping Zhang, Doctor, Dongsheng Zhang, PHD, Professor, Xuemei Wang, PHD, Professor

Blood (2013) 122 (21): 5038.

https://doi.org/10.1182/blood.V122.21.5038.5038

Published: 2013

Journal Articles

A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.

Manish Sharma, MD, Peter Thall, PhD, Xuemei Wang, PhD, Chitra Hosing, MD, Floralyn L Mendoza, MD, Eric Han, MD, Michael Wang, MD, Donna Weber, MD, Jatin Shah, MD, Amin Alousi, MD, Paolo Anderlini, MD, Partow Kebriaei, MD, Issa F Khouri, MD, Uday Popat, MD, Marcos de Lima, MD, Richard E Champlin, MD, Sergio Giralt, MD, Muzaffar Qazilbash, MD

Blood (2009) 114 (22): 2309.

https://doi.org/10.1182/blood.V114.22.2309.2309

Published: 2009

Journal Articles

Identifying Relapsed AML Patients Most Likely To Benefit from Allogeneic Stem Cell Transplant: A Statistical Subgroup Analysis.

Paul M. Armistead, MD, PhD, Marcos de Lima, MD, Sherry Pierce, RN, Wei Qiao, PhD, Xuemei Wang, PhD, Peter Thall, PhD, Sergio Giralt, MD, Richard Champlin, MD, Elihu Estey, MD

Blood (2007) 110 (11): 329.

https://doi.org/10.1182/blood.V110.11.329.329

Published: 2007

NARROW

Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in First Remission Improves Outcome Irrespective of FLT3-ITD Allelic Burden Among Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation

Other Cancers in Long-Term Survivors of Chronic Lymphocytic Leukemia: Incidence and Prognostic Relevance

Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML)

Antitumor Efficacy Of DMSA Modified Fe 3 O 4 magnetic Nanoparticles Combined With Arsenic Trioxide and Adriamycin In Jurket Cells

Gambogic Acid Combined With CdTe QDs For Leukemia Cancer Cells Inhibition and Their Bio-Safety For Rat Brain

Hyperthermia Enhances The Effect Of Magnetic Fe 3 O 4 nanoparticle Loaded With Daunorubicin On Leukemia and Drug Accumulation In Tumor In Vivo

A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.

Identifying Relapsed AML Patients Most Likely To Benefit from Allogeneic Stem Cell Transplant: A Statistical Subgroup Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only